Thus, blocking the MDM-mediated immunosuppressive microenvironment with the LGALS3 inhibitor GB1107 in combination with the HDAC7 inhibitor SAHA may be an effective way to treat GBM. This evidence concerns the gene LGALS3 and glioblastoma.